

CITATION REPORT

List of articles citing

Hydroxychloroquine: from malaria to autoimmunity

DOI: 10.1007/s12016-010-8243-x

Clinical Reviews in Allergy and Immunology, 2012, 42, 145-53

Source: <https://exaly.com/paper-pdf/54421522/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
418	Activation of the alternative NFB pathway improves disease symptoms in a model of Sjogren's syndrome. 2011 , 6, e28727		24
417	Autophagic activity measured in whole rat hepatocytes as the accumulation of a novel BHMT fragment (p10), generated in amphisomes by the asparaginyl proteinase, legumain. 2011 , 7, 1011-27		19
416	Discovering thiamine transporters as targets of chloroquine using a novel functional genomics strategy. 2012 , 8, e1003083		18
415	Evidence for risk of cardiomyopathy with hydroxychloroquine. 2012 , 21, 1594-6		22
414	Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort. 2012 , 51, 1293-8		39
413	Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity. 2012 , 249, 176-94		73
412	Use of disease-modifying antirheumatic drugs during pregnancy and risk of preeclampsia. 2012 , 64, 1730-8		15
411	Antimalarial drug chloroquine counteracts activation of indoleamine (2,3)-dioxygenase activity in human PBMC. 2012 , 2, 241-5		14
410	Identification of anti-malarial compounds as novel antagonists to chemokine receptor CXCR4 in pancreatic cancer cells. 2012 , 7, e31004		47
409	The origin and properties of extracellular DNA: from PAMP to DAMP. 2012 , 144, 32-40		139
408	Chloroquine: modes of action of an undervalued drug. 2013 , 153, 50-7		92
407	A rapid and reliable method for the quantitation of hydroxychloroquine in serum using turbulent flow liquid chromatography-tandem mass spectrometry. 2013 , 421, 79-84		33
406	Structural and some medicinal characteristics of the copper(II)-hydroxychloroquine complex. 2013 , 23, 4453-8		8
405	Improving outcomes in patients with lupus and end-stage renal disease. 2013 , 26, 590-6		15
404	Autoimmunity in 2012. <i>Clinical Reviews in Allergy and Immunology</i> , 2013 , 45, 290-301	12.3	15
403	Chloroquine cardiomyopathy - a review of the literature. 2013 , 35, 434-42		120
402	Hydroxychloroquine preferentially induces apoptosis of CD45RO+ effector T cells by inhibiting autophagy: a possible mechanism for therapeutic modulation of T cells. 2013 , 131, 1443-6.e1		34

401	CONCURRENT WHOLE BRAIN RADIOTHERAPY AND SHORT-COURSE CHLOROQUINE IN PATIENTS WITH BRAIN METASTASES: A PILOT TRIAL. 2013 , 2, 315		44
400	Serious Non-AIDS events: Immunopathogenesis and interventional strategies. 2013 , 10, 29		41
399	Unmet needs in respiratory diseases : "You can't know where you are going until you know where you have been"--Anonymous. <i>Clinical Reviews in Allergy and Immunology</i> , 2013 , 45, 303-13	12.3	4
398	Modulation of neutrophil NETosis: interplay between infectious agents and underlying host physiology. 2013 , 35, 439-53		73
397	Hydroxychloroquine niosomes: a new trend in topical management of oral lichen planus. 2013 , 458, 287-95		52
396	Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review. 2013 , 2013, 794383		17
395	Reciprocal effects of rab7 deletion in activated and neglected T cells. 2013 , 9, 1009-23		21
394	Current world literature. 2013 , 25, 275-83		
393	The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations. 2013 , 22, 3667-79		77
392	Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. 2013 , 41, 3947-61		56
391	Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation. 2013 , 112, 1159-70		181
390	Small molecule inhibitors of CXCR4. 2013 , 3, 47-75		195
389	Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. 2013 , 68, 766-71		97
388	Cardiovascular involvement in autoimmune diseases. 2014 , 2014, 367359		39
387	Development of polyether urethane intravaginal rings for the sustained delivery of hydroxychloroquine. 2014 , 8, 1801-15		15
386	Antiprotozoal Drugs. 2014 , 393-400		
385	Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications. 2014 , 66, 1619-26		55
384	Effect of hydroxychloroquine on the lipid profile of patients with Sjögren syndrome. 2014 , 41, 902-8		16

383	Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function. 2014 , 71, 154-64	60
382	Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. 2014 , 30, 1706-15	92
381	Pharmacology of Chloroquine and Hydroxychloroquine. 2014 , 35-63	65
380	Drug repurposing and human parasitic protozoan diseases. 2014 , 4, 95-111	218
379	Design and evaluation of a highly sensitive nanostructure-based surface modification of glassy carbon electrode for electrochemical studies of hydroxychloroquine in the presence of acetaminophen. 2014 , 123, 648-56	21
378	A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. 2014 , 5, 77-85	52
377	Approaches for detecting lysosomal alkalization and impaired degradation in fresh and cultured RPE cells: evidence for a role in retinal degenerations. 2014 , 126, 68-76	52
376	Signaling of chloroquine-induced stress in the yeast <i>Saccharomyces cerevisiae</i> requires the Hog1 and Slt2 mitogen-activated protein kinase pathways. 2014 , 58, 5552-66	12
375	Repositioning: the fast track to new anti-malarial medicines?. 2014 , 13, 143	29
374	Challenges for lupus management in emerging countries. 2014 , 43, e209-20	16
373	NF- κ -Mediated Regulation of Osteoclastogenesis. 2015 , 30, 35-44	171
372	The Role of Autophagy in Lupus Nephritis. 2015 , 16, 25154-67	38
371	Quinidine, but not eicosanoid antagonists or dexamethasone, protect the gut from platelet activating factor-induced vasoconstriction, edema and paralysis. 2015 , 10, e0120802	5
370	Multiwalled carbon nanotube-modified electrode as a nanosensor for electrochemical studies and stripping voltammetric determination of an antimalarial drug. 2015 , 5, 14407-14415	16
369	A new trick for an ancient drug: quinine dissociates antiphospholipid immune complexes. 2015 , 24, 32-41	5
368	Selective inhibition of extracellular oxidants liberated from human neutrophils--A new mechanism potentially involved in the anti-inflammatory activity of hydroxychloroquine. 2015 , 28, 175-81	13
367	Screening and vaccinations in patients requiring systemic immunosuppression: an update for dermatologists. 2015 , 16, 179-95	5
366	Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. 2015 , 23, 231-69	300

365	Hydroxychloroquine reduces microglial activity and attenuates experimental autoimmune encephalomyelitis. 2015 , 358, 131-7	33
364	Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases. 2015 , 50, 410-9	30
363	Treatment of severe lupus nephritis: the new horizon. 2015 , 11, 46-61	67
362	Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. 2015 , 35, 143-56	65
361	Pharmacologic management of pain in patients with Chikungunya: a guideline. 2016 , 49, 668-679	30
360	Th-17 related regulatory network in the pathogenesis of Arab patients with systemic lupus erythematosus and lupus nephritis. 2016 , 19, 512-20	10
359	Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug Interactions. 2016 , 13, 839-51	22
358	[Immunomodulatory therapy of autoimmune diseases : Quo vadis?]. 2016 , 113, 373-9	0
357	Hydroxychloroquine is ineffective in treatment of alopecia totalis and extensive alopecia areata: A case series of 8 patients. 2016 , 2, 117-8	9
356	Discoveries of conventional synthetic disease modifying anti-rheumatic drugs Berendipity or flawless reasoning?. 2016 , 11, 32-38	3
355	Hydroxychloroquine binding to cytoplasmic domain of Band 3 in human erythrocytes: Novel mechanistic insights into drug structure, efficacy and toxicity. 2016 , 473, 999-1004	4
354	Synthesis and anodic electrochemistry of cyanquinone and related complexes. 2016 , 817, 15-20	10
353	Enzymatic and thermodynamic profiles of a heterotetramer lactate dehydrogenase isozyme in swine. 2016 , 479, 860-867	4
352	Immunomodulatory proteins FIP-gts and chloroquine induce caspase-independent cell death via autophagy for resensitizing cisplatin-resistant urothelial cancer cells. 2016 , 23, 1566-1573	23
351	Autophagy is associated with chemoresistance in neuroblastoma. 2016 , 16, 891	46
350	Increased autophagy in CD4 T cells of rheumatoid arthritis patients results in T-cell hyperactivation and apoptosis resistance. 2016 , 46, 2862-2870	50
349	Compendium of Inflammatory Diseases. 2016 , 5-20	1
348	Compendium of Inflammatory Diseases. 2016 , 117-129	

347	Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. 2016 , 81, 835-48	56
346	Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?. 2016 , 46, 291-304	84
345	Upcoming therapeutic targets in cutaneous lupus erythematosus. 2016 , 9, 567-578	14
344	Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development. 2016 , 38, 2-13	31
343	Effect of hydroxychloroquine and characterization of autophagy in a mouse model of endometriosis. 2016 , 7, e2059	52
342	Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection. 2016 , 76, 533-49	36
341	Autophagy inhibitors. 2016 , 73, 985-1001	157
340	Pharmacologic management of neuropsychiatric lupus. 2016 , 9, 103-8	5
339	Is there still a place for "old therapies" in the management of immune thrombocytopenia?. 2016 , 37, 43-9	21
338	Chloroquine rescues A549 cells from paraquat-induced death. 2016 , 39, 167-73	5
337	Adherence to Hydroxychloroquine Dosing Guidelines by Rheumatologists: An Electronic Medical Record-Based Study in an Integrated Health Care System. 2017 , 124, 604-608	12
336	Chloroquine attenuates TLR3/IFN- β signaling in cultured normal human mesangial cells: A possible protective effect against renal damage in lupus nephritis. 2017 , 27, 1004-1009	10
335	Low prevalence of Pneumocystis pneumonia in hospitalized patients with systemic lupus erythematosus: review of a clinical data warehouse. 2017 , 26, 1473-1482	12
334	Global survey of the immunomodulatory potential of common drugs. 2017 , 13, 681-690	33
333	BMP type II receptor as a therapeutic target in pulmonary arterial hypertension. 2017 , 74, 2979-2995	54
332	Use of Hydroxychloroquine Is Associated With Improved Lipid Profile in Rheumatoid Arthritis Patients. 2017 , 23, 144-148	12
331	Updated recommendations on the use of hydroxychloroquine in dermatologic practice. 2017 , 76, 1176-1182	29
330	Hydroxychloroquine in systemic lupus erythematosus (SLE). 2017 , 16, 411-419	153

329	TLRs, future potential therapeutic targets for RA. 2017 , 16, 103-113	88
328	Hydroxychloroquine and joint involvement in systemic sclerosis: Preliminary beneficial results from a retrospective case-control series of an EUSTAR center. 2017 , 84, 747-748	12
327	Recomendações da Sociedade Brasileira de Reumatologia para diagnóstico e tratamento da febre chikungunya. Parte 2 - Tratamento. 2017 , 57, 438-451	20
326	Recommendations of the Brazilian Society of Rheumatology for the diagnosis and treatment of chikungunya fever. Part 2 - Treatment. 2017 , 57 Suppl 2, 438-451	9
325	Autophagy inhibition enabled efficient photothermal therapy at a mild temperature. 2017 , 141, 116-124	104
324	Desirable and Adverse Effects of Antiinflammatory Agents on the Heart. 2017 , 617-643	0
323	A Case of Treatment with Steroid and Hydrochloroquine of Thrombocytopenia in Primary Sjögren's Syndrome. 2017 , 32, 118	
322	Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents. 2017 , 11, 781	133
321	Optimizing conventional DMARD therapy for Sjögren's syndrome. 2018 , 17, 480-492	15
320	Hydroxychloroquine attenuates renal ischemia/reperfusion injury by inhibiting cathepsin mediated NLRP3 inflammasome activation. 2018 , 9, 351	85
319	A new insight into effects of a clinically proved combination of methotrexate and hydroxychloroquine. 2018 , 149, 961-967	
318	Hydroxychloroquine Use and Risk of CKD in Patients with Rheumatoid Arthritis. 2018 , 13, 702-709	15
317	New use for an old treatment: Hydroxychloroquine as a potential treatment for systemic vasculitis. 2018 , 17, 660-664	21
316	Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update. 2018 , 30, 249-255	33
315	Implant delivering hydroxychloroquine attenuates vaginal T lymphocyte activation and inflammation. 2018 , 277, 102-113	10
314	Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. 2018 , 77, 98-103	117
313	Novel function of hydroxychloroquine: Down regulation of T follicular helper cells in collagen-induced arthritis. 2018 , 97, 838-843	8
312	Hydroxychloroquine et les atteintes articulaires dans la sclérodémie systémique: résultats préliminaires d'une étude rétrospective cas-témoins EUSTAR. 2018 , 85, 411-412	

311	Do Type I Interferons Link Systemic Autoimmunities and Metabolic Syndrome in a Pathogenetic Continuum?. 2018 , 39, 28-43	38
310	Chloroquine ameliorates carbon tetrachloride-induced acute liver injury in mice via the concomitant inhibition of inflammation and induction of apoptosis. 2018 , 9, 1164	66
309	Activity-guided development of potent and selective toll-like receptor 9 antagonists. 2018 , 159, 187-205	9
308	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. 2018 , 17, 1153-1168	43
307	Hydroxychloroquine fails to attenuate lesion development in a mouse model of neuromyelitis optica. 2018 , 24, 842-845	1
306	Antiparasitics (PC). 2018 , 1-22	
305	Optical Coherence Tomography Minimum Intensity as an Objective Measure for the Detection of Hydroxychloroquine Toxicity. 2018 , 59, 1953-1963	12
304	Autophagy Is a Tolerance-Avoidance Mechanism that Modulates TCR-Mediated Signaling and Cell Metabolism to Prevent Induction of T Cell Energy. 2018 , 24, 1136-1150	33
303	Mast Cells Are Activated by but Dispensable for the Host Defense Against Pneumococcal Central Nervous System Infection. 2018 , 9, 550	7
302	Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions. 2018 , 19,	42
301	Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. 2018 , 38, 653-671	152
300	A dual-mode nanoprobe for evaluation of the autophagy level affected by photothermal therapy. 2019 , 55, 9673-9676	6
299	Prevention of crystalline silica-induced inflammation by the anti-malarial hydroxychloroquine. 2019 , 31, 274-284	9
298	A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 2019 , 183, 111715	17
297	Automated Segmentation Measurements of the Outer Nuclear Layer in Determining Cases of Hydroxychloroquine Toxicity: A Retrospective Study. 2019 , 3, 135-144	2
296	Effects of hydroxychloroquine on the human placenta-Findings from in vitro experimental data and a systematic review. 2019 , 87, 50-59	7
295	New Applications of Old Drugs as Novel Therapies in Idiopathic Pulmonary Fibrosis. Metformin, Hydroxychloroquine, and Thyroid Hormone. 2019 , 199, 1561-1563	4
294	Protective autophagy elicited by RAF-MEK-ERK inhibition suggests a treatment strategy for RAS-driven cancers. 2019 , 25, 620-627	280

293	Hydroxychloroquine inhibits IL-1 β production from amyloid-stimulated human neutrophils. 2019 , 21, 250	13
292	Wide field retinal imaging and the detection of drug associated retinal toxicity. 2019 , 5, 26	7
291	IITZ-01, a novel potent lysosomotropic autophagy inhibitor, has single-agent antitumor efficacy in triple-negative breast cancer in vitro and in vivo. 2019 , 38, 581-595	19
290	Revisiting the Cardiotoxic Effect of Chloroquine. 2019 , 33, 1-11	25
289	[Drug-induced Sweet's syndrome related to hydroxychloroquine: About 2 cases]. 2020 , 41, 289-292	2
288	An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: A systematic review. 2020 , 82, 709-722	12
287	Systemic lupus erythematosus and hydroxychloroquine-related acute intermittent porphyria. 2020 , 40, 777-783	3
286	Hydroxychloroquine Retinopathy in the Era of Advanced Imaging Modalities. 2020 , 60, 73-83	0
285	Successful treatment with hydroxychloroquine for systemic lupus erythematosus with cutaneous involvement accompanied by a xanthomatous reaction. 2020 , 29, 79-82	2
284	Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders - A comprehensive systematic review and meta-analysis. 2020 , 90, 364-380	25
283	Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. 2020 , 216, 107672	31
282	Preparation and physicochemical stability of 50 mg/mL hydroxychloroquine oral suspension in SyrSpend SF PH4 (dry). 2020 , 56, 106201	1
281	Potential of tilapia (<i>Oreochromis niloticus</i>) viscera bioactive peptides as antiviral for SARS-CoV-2 (COVID 19). 2020 , 584, 012004	4
280	Primary cutaneous low-grade B-cell lymphoma treated with hydroxychloroquine. 2020 , 6, 1048-1050	0
279	Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial. 2021 , 73, e4073-e4081	150
278	Pharmaco-Immunomodulatory Therapy in COVID-19. 2020 , 80, 1267-1292	128
277	Chloroquine as a promising adjuvant therapy for type 1 Diabetes Mellitus. 2020 , 10, 12098	2
276	Degradation of hydroxychloroquine by electrochemical advanced oxidation processes. 2020 , 402, 126279	34

275	The Cardiovascular Effects of Treatment with Hydroxychloroquine and Azithromycin. 2020 , 40, 978-983	4
274	Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy. 2020 , 21,	11
273	Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection. 2020 , 108, 1135-1149	17
272	Insights in Chloroquine Action: Perspectives and Implications in Malaria and COVID-19. 2020 , 97, 872-881	6
271	Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making. 2020 , 46, 574-578	8
270	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). 2020 , 7, 572485	10
269	Pharmacogenomics of genetic polymorphism within the genes responsible for SARS-CoV-2 susceptibility and the drug-metabolising genes used in treatment. 2021 , 31, e2194	6
268	Determination of potential inhibitors based on isatin derivatives against SARS-CoV-2 main protease (m): a molecular docking, molecular dynamics and structure-activity relationship studies. 2020 , 1-19	24
267	Side Effects of Chloroquine and Hydroxychloroquine on Skeletal Muscle: a Narrative Review. 2020 , 6, 1-9	10
266	Molecular effects and retinopathy induced by hydroxychloroquine during SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations. 2020 , 886, 173454	7
265	Emerging Therapeutic Modalities against COVID-19. 2020 , 13,	11
264	The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients. 2020 , 62, 59-64	13
263	Management of patients with Behçet's disease during the COVID-19 pandemic. 2020 , 33, e14063	10
262	Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. 2020 , 11, 1708	441
261	Evaluation of Current Therapies for COVID-19 Treatment. 2020 , 8,	9
260	High affinity interaction of Solanum tuberosum and Brassica juncea residue smoke water compounds with proteins involved in coronavirus infection. 2020 , 34, 3400-3410	4
259	Antimalarials as Antivirals for COVID-19: Believe it or Not!. 2020 , 360, 618-630	14
258	Targeting Crucial Host Factors of SARS-CoV-2. 2020 , 6, 2844-2865	13

257	Hydroxychloroquine Exhibits a Strong Complex Interaction with DNA: Unraveling the Mechanism of Action. 2020 , 11, 9528-9534	7
256	Spermidine endows macrophages anti-inflammatory properties by inducing mitochondrial superoxide-dependent AMPK activation, Hif-1 α upregulation and autophagy. 2020 , 161, 339-350	12
255	Hydroxychloroquine effects on miR-155-3p and miR-219 expression changes in animal model of multiple sclerosis. 2020 , 35, 1299-1307	7
254	Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings. 2020 , 22, 1855-1863	19
253	Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic~Strategies. 2020 , 21,	32
252	Viral Vectors Applied for RNAi-Based Antiviral Therapy. 2020 , 12,	11
251	COVID-19 Outbreak: Pathogenesis, Current Therapies, and Potentials for Future Management. 2020 , 11, 563478	30
250	Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial Therapies, Supportive Care, and Probable Vaccines. 2020 , 11, 582025	11
249	C-C chemokine receptor type 5 links COVID-19, rheumatoid arthritis, and Hydroxychloroquine: in silico analysis. 2020 , 5, 14	3
248	Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection. 2020 , 57, 4856-4877	20
247	COVID-19 Pandemic: from Molecular Biology, Pathogenesis, Detection, and Treatment to Global Societal Impact. 2020 , 6, 1-16	21
246	Trials of treatments for COVID-19: Review of drugs are tested. 2020 , 1664, 012086	1
245	Current Trends in Analytical Methods for the Determination of Hydroxychloroquine and Its Application as Treatment for COVID-19. 2020 , 5, 14602-14612	4
244	Disinformation and Conspiracy Theories in the Age of COVID-19. 2020 , 5, 560681	7
243	Coronavirus pandemic: treatment and future prevention. 2020 , 15, 1507-1521	1
242	In-line treatments and clinical initiatives to fight against COVID-19 outbreak. 2020 , 106192	6
241	COVID-19 pneumonia in kidney transplant recipients-Where we are?. 2020 , 22, e13306	19
240	Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. 2020 , 108, 775-790	75

239	The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?. 2020 , 158, 104904	72
238	Efficacy, safety and cost-effectiveness of hydroxychloroquine in children with COVID-19: A call for evidence. 2020 , 109, 1711-1712	4
237	SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management. 2020 , 178, 114114	46
236	Risk of using hydroxychloroquine as a treatment of COVID-19. 2020 , 31, 111-116	17
235	Drug treatment of coronavirus disease 2019 (COVID-19) in China. 2020 , 883, 173326	15
234	Natural history of COVID-19 and current knowledge on treatment therapeutic options. 2020 , 129, 110493	59
233	SARS, MERS and COVID-19: clinical manifestations and organ-system complications: a mini review. 2020 , 78,	31
232	Is hydroxychloroquine beneficial for COVID-19 patients?. 2020 , 11, 512	57
231	Epidemic and pandemic viral infections: impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC). 2020 , 56,	42
230	The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. 2020 , 19, 102491	38
229	Candidate drugs against SARS-CoV-2 and COVID-19. 2020 , 157, 104859	304
228	Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. 2020 ,	11
227	Covid-19 treatment update: follow the scientific evidence. 2020 , 50, 43-53	24
226	COVID-19: Immunology and treatment options. 2020 , 215, 108448	321
225	Clinical Trials during the SARS-CoV-2 Pandemic. 2020 , 144, 248-250	3
224	Respiratory conditions in coronavirus disease 2019 (COVID-19): Important considerations regarding novel treatment strategies to reduce mortality. 2020 , 140, 109760	48
223	Chloroquine and Hydroxychloroquine in the Era of SARS - CoV2: Caution on Their Cardiac Toxicity. 2020 , 40, 387-388	21
222	Opportunistic tropical infections in immunosuppressed patients. 2020 , 34, 101509	10

221	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). 2020 , 7, ofaa130	122
220	Hydroxychloroquine and COVID-19. 2020 , 96, 550-555	77
219	Drug rechanneling: A novel paradigm for cancer treatment. 2021 , 68, 279-290	12
218	Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria. 2021 , 35, 343-348	7
217	Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead. 2021 , 890, 173717	14
216	Torsades de Pointes in Coronavirus Disease 2019 Infection. 2021 , 35, 954-955	0
215	Hydroxychloroquine and the treatment of Sjogren syndrome, chronic ulcerative stomatitis, and oral lichen planus in the age of COVID-19. 2021 , 131, e9-e13	1
214	Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection. 2021 , 538, 156-162	4
213	Successful treatment with oral hydroxychloroquine of seborrhoeic dermatitis in a patient with AIDS. 2021 , 46, 567-568	
212	Idiopathic pulmonary hemosiderosis: a review of the treatments used during the past 30 years and future directions. 2021 , 40, 2547-2557	13
211	The unfinished story of hydroxychloroquine in COVID-19: The right anti-inflammatory dose at the right moment?. 2021 , 103, 1-2	8
210	COVID-19: A review of therapeutic strategies and vaccine candidates. 2021 , 222, 108634	109
209	Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study. 2021 , 84, 930-937	8
208	Evaluation of corneal safety in systemic lupus erythematosus patients undergoing long-term hydroxychloroquine treatment. 2021 , 40, 21-25	0
207	Polydopamine-based nanomaterials and their potentials in advanced drug delivery and therapy. 2021 , 199, 111502	25
206	An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy. 2021 , 103, 599-606	4
205	Recent progress of antiviral therapy for coronavirus disease 2019. 2021 , 890, 173646	16
204	[Monocentric study on pharmaceuticals taken by patients to treat systemic sclerosis]. 2021 , 42, 86-92	

203	Chloroquine (antimalaria medication with anti SARS-CoV activity) solubility in supercritical carbon dioxide. 2021 , 322, 114539	14
202	Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports. 2021 , 87, 1432-1442	26
201	Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus. 2021 , 117, 2309-2325	10
200	Malaria in the Pregnant Women. 2021 , 383-398	
199	Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery. 2021 , 17, 1538-1546	12
198	Investigation of the Therapeutic Effects of Chloroquine in Adriamycin-Induced Hepatotoxicity. 2021 , 5, 8-14	
197	Systematic review and meta-analysis of efficacy and safety of hydroxychloroquine and chloroquine in the treatment of COVID-19. 2021 , 10, 2126-2139	1
196	Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes. 2021 , 180, 356-368	7
195	Pre-Exposure Prophylaxis for COVID-19 in Pregnant Women. 2021 , 14, 279-284	4
194	Hydroxychloroquine (HCQ) and its Synthetic Precursors: A Review. 2021 , 18,	0
193	Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. 2021 , 2, CD013587	57
192	Impact of hydroxychloroquine on disease progression and ICU admissions in patients with SARS-CoV-2 infection. 2021 , 78, 689-696	3
191	Effects of Chloroquine and Hydroxychloroquine on the Cardiovascular System - Limitations for Use in the Treatment of COVID-19. 2021 ,	1
190	COVID-19: Immunology, Immunopathogenesis and Potential Therapies. 2021 , 1-36	11
189	Hydroxychloroquine Sulfate Related Hypoglycemia In A Non-Diabetic COVID-19 Patient: A Case Report and Literature Review. 2021 , 133, 548-551	3
188	Quantum chemical studies on molecular structure, AIM, ELF, RDG and antiviral activities of hybrid hydroxychloroquine in the treatment of COVID-19: Molecular docking and DFT calculations. 2021 , 33, 101334	16
187	In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV. 2021 , 10, 22	3
186	Fisetin inhibits inflammation and induces autophagy by mediating PI3K/AKT/mTOR signaling in LPS-induced RAW264.7 cells. 2021 , 65,	1

185	Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review. 2021 , 61, 429-460	13
184	Nanomedicine Technology and COVID-19 Outbreak: Applications and Challenges. 2021 , 06, 161-174	5
183	COVID-19, hydroxychloroquine and the importance of disease progression. 2021 , 10, 299-311	1
182	Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting. 2021 , 29, 343-366	6
181	Hydroxychloroquine Effects on TLR Signalling: Underexposed but Unneglectable in COVID-19. 2021 , 2021, 6659410	2
180	Hydroxychloroquine Does Not Increase the Risk of Cardiac Arrhythmia in Common Rheumatic Diseases: A Nationwide Population-Based Cohort Study. 2021 , 12, 631869	1
179	Cardiac TdP risk stratification modelling of anti-infective compounds including chloroquine and hydroxychloroquine. 2021 , 8, 210235	3
178	Therapeutic Agents for COVID-19: an Overview. 2021 , 16, 22-44	1
177	SARS-CoV-2 Therapy: Old Drugs as New Interventions. 2021 , 2, 142-150	1
176	New Trends On Biological Activities And Clinical Studies Of Quinolinic Analogues: A Review. 2021 ,	
175	Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. 2021 , 60, S125-S136	5
174	Three Infants with Pathogenic Variants in the ABCA3 Gene: Presentation, Treatment, and Clinical Course. 2021 , 231, 278-283.e2	1
173	Chloroquine: Autophagy inhibitor, antimalarial, bitter taste receptor agonist in fight against COVID-19, a reality check?. 2021 , 897, 173928	8
172	Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase. 2021 , 77, 1513-1521	2
171	Modelling sudden cardiac death risks factors in patients with coronavirus disease of 2019: the hydroxychloroquine and azithromycin case. 2021 , 23, 1124-1133	2
170	Treatment patterns in US patients hospitalized with COVID-19 and pulmonary involvement. 2021 , 93, 5367-5375	5
169	Development of a SARS-CoV-2-derived receptor-binding domain-based ACE2 biosensor. 2021 , 334, 129663	4
168	Covid-19da Kullanılan İlaçların Hesapsal İlişkileri	

- 167 The evolution of knowledge on genes associated with human diseases.
- 166 Blocking the interactions between human ACE2 and coronavirus spike glycoprotein by selected drugs: a computational perspective. **2021**, 36, e2021010-0 1
- 165 Effect of Hydroxychloroquine on Lipid Levels: A Systematic Review and Metaanalysis. **2021**, 27, 4133-4139 2
- 164 Proteomics advances towards developing SARS-CoV-2 therapeutics using in silico drug repurposing approaches. **2021**, 3
- 163 Coronavirus Disease 2019 (COVID-19): Origin, Impact, and Drug Development. 1
- 162 Groove Switching of Hydroxychloroquine Modulates the Efficacy of Binding and Induced Stability to DNA. **2021**, 125, 6889-6896 3
- 161 COVID-19 Global Pandemic Fight by Drugs: A Mini-Review on Hope and Hype. **2021**, 18,
- 160 The Therapeutic Potential of Targeting Autophagy in The Treatment of Cancer. **2021**, 1
- 159 Chloroquine and hydroxychloroquine in antitumor therapies based on autophagy-related mechanisms. **2021**, 168, 105582 10
- 158 PD-1-siRNA Delivered by Attenuated Enhances the Antitumor Effect of Chloroquine in Colon Cancer. **2021**, 12, 707991 0
- 157 OCT retinal angiography features in patients with rheumatoid arthritis: A pilot study. **2021**, 11206721211035626
- 156 COVID-19 and the Challenges of Chemotherapy: The Failure Case of Hydroxychloroquine in the Clinical Treatment of SARS-CoV-2 Infection. **2021**, 2,
- 155 A systematic review and meta-analysis of the safety of Hydroxychloroquine in a randomized controlled trial and observational studies. **2021**,
- 154 One microsecond MD simulations of the SARS-CoV-2 main protease and hydroxychloroquine complex reveal the intricate nature of binding. **2021**, 1-8 1
- 153 Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic. **2021**, 1 3
- 152 Neural simulation and experimental investigation of Chloroquine solubility in supercritical solvent. **2021**, 333, 115942 6
- 151 Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19. **2021**, 3
- 150 Association between Hydroxychloroquine and bacterial pneumonia in rheumatic patients: A population-based propensity score matching cohort study. **2021**, 75, e14737 1

149	Development and Validation of a Simple and Rapid Ultrahigh-Performance Liquid Chromatography Tandem Spectrometry Method for the Quantification of Hydroxychloroquine in Plasma and Blood Samples in the Emergency Context of SARS-CoV-2 Pandemic. 2021 , 43, 570-576	4
148	Novel Therapeutic Interventions in Systemic Lupus Erythematosus.	
147	Targeted and Non-Targeted Mechanisms for Killing Hypoxic Tumour Cells-Are There New Avenues for Treatment?. 2021 , 22,	
146	Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials. 2021 , 93, 6737-6749	4
145	Hydroxychloroquine Prophylaxis against Coronavirus Disease-19: Practice Outcomes among Health-Care Workers.	
144	Association between increased Bcl-2, Fas and FasL levels and inflammation extent in labial salivary glands during primary Sjögren's syndrome. 2021 ,	0
143	Aminoquinolines as Translational Models for Drug Repurposing: Anticancer Adjuvant Properties and Toxicokinetic-Related Features. 2021 , 2021, 3569349	0
142	Nanoparticles as an effective drug delivery system in COVID-19. 2021 , 143, 112162	4
141	MFN2 Stabilization: A Bridge for Endoplasmic Reticulum Stress Sensitivity in Melanoma. 2021 , 141, 2782-2784	
140	Design of the Healthcare Worker Exposure Response and Outcomes (HERO) research platform. 2021 , 109, 106525	0
139	Environmental impacts of COVID-19 treatment: Toxicological evaluation of azithromycin and hydroxychloroquine in adult zebrafish. 2021 , 790, 148129	2
138	On the importance of physicochemical parameters of copper and aminosilane functionalized mesoporous silica for hydroxychloroquine release. 2021 , 130, 112438	2
137	Hydroxychloroquine and Chloroquine in Prophylaxis and Treatment of COVID-19: What Is Known?. 2021 , 13, 4-10	0
136	Hydroxychloroquine Inhibits Cardiac Conduction in Aged Patients with Nonmalaria Diseases. 2021 , 5, 1-10	0
135	Toxicology of Hydroxychloroquine and Chloroquine and the Pathology of the Retinopathy They Cause. 2014 , 65-83	3
134	Quantification of Hydroxychloroquine in Blood Using Turbulent Flow Liquid Chromatography-Tandem Mass Spectrometry (TFLC-MS/MS). 2016 , 1383, 177-84	3
133	Repurposing clinical drugs is a promising strategy to discover drugs against Zika virus infection. 2021 , 15, 404-415	4
132	Host-microbiota interactions in immune-mediated diseases. 2020 , 18, 521-538	94

131	Unconventional secretion of FABP4 by endosomes and secretory lysosomes. 2018 , 217, 649-665	41
130	Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics.	11
129	The Anti-histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits SARS-CoV-2 Infection in Reconstituted Human Nasal Tissue In Vitro.	3
128	COVID-19: Disease Pattern Study based on Semantic-Web Approach using Description Logic. 2020 ,	3
127	Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation. 2014 , 124, 297-310	101
126	SARS-CoV-2 Infection and COVID-19 in 5 Patients in Ecuador After Prior Treatment with Hydroxychloroquine for Systemic Lupus Erythematosus. 2020 , 21, e927304	4
125	Hydroxychloroquine Destabilizes Phospho-S6 in Human Renal Carcinoma Cells. 2015 , 10, e0131464	15
124	Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood. 2020 , 58, 2047-2061	4
123	Hydroxychloroquine in rheumatic autoimmune disorders and beyond. 2020 , 12, e12476	29
122	COVID-19: therapeutic approaches description and discussion. 2020 , 92, e20200466	6
121	Pro-apoptotic effect of doxycycline and hydroxychloroquine on B-cell lymphoma induced by. 2018 , 9, 2726-2727	3
120	Chloroquine / Hydroxychloroquine: Pharmacological view of an old drug currently used in COVID-19 treatment. 204-215	0
119	Dermatologists' Adherence to the Latest Recommendations for Screening of Hydroxychloroquine Retinopathy in Saudi Arabia: Cross-Sectional Study. 2019 , 8, e15218	2
118	Repurposing current therapeutic regimens against SARS-CoV-2 (Review). 2020 , 20, 1845-1855	4
117	Towards a more effective strategy for COVID-19 prevention (Review). 2021 , 21, 33	2
116	The VR23 Antitumor Compound Also Shows Strong Anti-Inflammatory Effects in a Human Rheumatoid Arthritis Cell Model and Acute Lung Inflammation in Mice. 2020 , 204, 788-795	4
115	Anti-inflammatory and Immunomodulatory Effects of Antibiotics and Their Use in Dermatology. 2016 , 61, 469-81	39
114	Hydroxychloroquine retinopathy: A review of imaging. 2015 , 63, 570-4	16

113	Wide Applications of Chloroquine Other Than Antimalarial. 2020 , 11, 251-281	1
112	Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with COVID-19. 2020 , 102, 1214-1216	34
111	Mitochondrial oxidative phosphorylation and mitophagy in myocardial ischaemia/reperfusion: effects of chloroquine. 2020 , 31, 169-179	1
110	Microperimetry in hydroxychloroquine macular toxicity.. 2021 , 65, 235-240	1
109	Pharmacokinetics and Toxicokinetics of Artemisinin-Hydroxychloroquine Sulfate Tablets in Rats and Dogs. 2021 , 2021, 6830459	1
108	Antiprotozoal agents: How have they changed over a decade?. 2021 , e2100338	1
107	Novel coronavirus pathogen in humans and animals: an overview on its social impact, economic impact, and potential treatments. 2021 , 28, 68071	4
106	COVID-19 Prevalence and Outcomes among Individuals with Rheumatoid Arthritis and Systemic Lupus Erythematosus Taking Hydroxychloroquine; A Retrospective Analysis. 2021 , 15, 69-76	1
105	Effects of Hydroxychloroquine on Retinal Vessel Density in Patients with Rheumatoid Arthritis over One-Year Follow-Up: A Pilot Study. 2021 , 11, 9837	
104	Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19. 2021 , 144, 112276	3
103	Encyclopedia of Inflammatory Diseases. 2013 , 1-6	
102	Pharmakotherapie. 2014 , 121-168	
101	Risk Factors for Hydroxychloroquine and Chloroquine Retinopathy. 2014 , 133-154	
100	Compendium of Inflammatory Diseases. 2016 , 105-116	
99	Compendium of Inflammatory Diseases. 2016 , 97-101	
98	Pharmacotherapy of Rheumatoid Arthritis. 2016 , 19-37	
97	CHAPTER 5:Oligonucleotide-based Toll-like Receptor Antagonists and Therapeutic Applications. 2019 , 80-102	
96	Current Status of Treatment Options, Clinical Trials, and Vaccine Development for SARS-CoV-2 Infection. 2020 , 14, 733-740	2

- 95 Treatment of COVID19 with antimalarial medicines: clinical pharmacology analysis. **2020**, 22, 164-174
- 94 Hydroxychloroquine: the story of one drug during the COVID-19 pandemic. **2020**, 123, 74
- 93 Hydroxychloroquine dosing and toxicity: A real-world experience in Saudi Arabia of 63 patients. **2020**, 34, 151-155 2
- 92 THE ROLE OF HYDROXYCHLOROQUINE IN THE TREATMENT OF HIV AND COVID-19: A REVIEW.. **2020**, 9, 20-29
- 91 Evaluating the Use of Hydroxychloroquine in Treating Patients With Rheumatoid Arthritis. **2021**, 13, e19308 0
- 90 Evaluation of azithromycin or hydroxychloroquine plus azithromycin combination therapy on cardiac conduction and function in guinea pigs.
- 89 COVID-19 ON BEHETS DISEASE PATIENT : SHED LIGHT ON SHADOWS (CASE REPORT). **2020**, 8, 49-52
- 88 Treatment and therapeutic agents. **2022**, 121-176
- 87 Ethical challenges of prospective clinical trials during the COVID-19 pandemic. **2021**, 1-6
- 86 Treatment of SARS-CoV-2 (COVID-19): A safety perspective. **2021**, 10, 1-32 0
- 85 Hydroxychloroquine prophylaxis against coronavirus disease-19: Knowledge and practice among health-care professionals. **2020**, 9, 38
- 84 Acute and subacute oral toxicity of artemisinin-hydroxychloroquine sulfate tablets in rats.. **2022**, 129, 105114 2
- 83 Electrochemical sensor based on a chitosan-molybdenum vanadate nanocomposite for detection of hydroxychloroquine in biological samples.. **2022**, 613, 1-14 6
- 82 Detailed Comparison between the Safety Profiles of Chloroquine and Hydroxychloroquine. **2021**, 7, 4
- 81 Hydroxychloroquine's Influence on Hypoxic and Hypokalemic ventricle: An Insilico Perspective. **2021**,
- 80 Does the influence of hydroxychloroquine in a hypoxic ventricle differ from that of a non-hypoxic ventricle under congenital LQTS1 ?. **2021**,
- 79 Decomposition mechanism of hydroxychloroquine in aqueous solution by gamma irradiation.. **2022**, 76, 1-11 0
- 78 The pharmacotherapeutics of sarcoidosis.. **2022**, 1-14

77	The Ototoxicity of Chloroquine and Hydroxychloroquine: A Systematic Review.. 2022 , 26, e167-e177	
76	Lysosomes are Required for Early Dorsal Signaling in the <i>Xenopus</i> Embryo.	
75	Arrhythmogenic mechanisms of interleukin-6 combination with hydroxychloroquine and azithromycin in inflammatory diseases.. 2022 , 12, 1075	3
74	Synthesis and Applications of Asymmetric Catalysis Using Chiral Ligands Containing Quinoline Motifs. 2022 , 06, 31-57	0
73	The evolution of knowledge on genes associated with human diseases.. 2022 , 25, 103610	1
72	Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies.. 2022 , 132,	2
71	New insights in pathogenic mechanism of hydroxychloroquine retinal toxicity through optical coherence tomography angiography analysis.. 2022 , 11206721221076313	1
70	Epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa.. 2022 , 103880	0
69	Synthesis, biological evaluation, Structure-Activity relationship studies of quinoline-imidazole derivatives as potent antimalarial agents.. 2022 , 121, 105671	1
68	How Microbiota Forms Rheumatic Diseases? Part 2. 2021 , 101-113	
67	Use of chloroquine and hydroxychloroquine in COVID-19 patients: A dilemma. 2022 , 3, 3	
66	Hydroxychloroquine pre-exposure prophylaxis for COVID-19 among healthcare workers: Initial experience from India.. 2022 , 11, 1140-1145	
65	Current therapeutic choices for coronavirus disease 2019: a state-of-the-art review. 2022 , 79-93	
64	-Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic.. 2022 , 58,	1
63	Melatonin in the Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers (MeCOVID): A Randomised Clinical Trial.. 2022 , 11,	2
62	Drug Repositioning in Intensive Care Patients and Pharmacokinetic Variability: The Illustration of Hydroxychloroquine. 2022 , 2, 92-98	
61	Hydroxychloroquine: Adverse Drug Reaction Profile of an Old Drug in a New Situation.. 2022 ,	
60	Hydroxychloroquine attenuates neuroinflammation following traumatic brain injury by regulating the TLR4/NF- κ B signaling pathway.. 2022 , 19, 71	2

- 59 Thuja Occidentalis: an Unexplored Phytomedicine with Therapeutic Applications.. **2022**,
- 58 An Update on Sjögren's Syndrome for Oral Medicine Specialists. **2021**, 46, 99-108
- 57 On Analysis of Banhatti Indices for Hyaluronic Acid Curcumin and Hydroxychloroquine. **2021**, 2021, 1-10 ○
- 56 Treatment of Cardiovascular Disease in Rheumatoid Arthritis: A Complex Challenge with Increased Atherosclerotic Risk.. **2021**, 15, 1
- 55 Emerging Role of Autophagy in the Development and Progression of Oral Squamous Cell Carcinoma.. **2021**, 13, ○
- 54 Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2.. **2022**, 14, ○
- 53 Hydroxychloroquine alleviates renal interstitial fibrosis by inhibiting the PI3K/Akt signaling pathway.. **2022**, 610, 154-161 ○
- 52 Table_1.DOCX. **2020**,
- 51 Image_1.JPEG. **2018**,
- 50 Image_2.JPEG. **2018**,
- 49 Image_3.JPEG. **2018**,
- 48 Table_1.xlsx. **2020**,
- 47 Lysosomes are required for early dorsal signaling in the embryo.. **2022**, 119, e2201008119 1
- 46 Pharmacological Management. **2022**, 67-96
- 45 Physiologically-Based Pharmacokinetics Modeling for Hydroxychloroquine as a Treatment for Malaria and Optimized Dosing Regimens for Different Populations. **2022**, 12, 796 ○
- 44 Chloroquine attenuates chronic hypoxia-induced testicular damage via suppressing endoplasmic reticulum stress and apoptosis in experimental rat model.. **2022**, ○
- 43 Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs). **2022**, 14, 1759720X2210902
- 42 Redox aspects of cytotoxicity and anti-neuroinflammatory profile of chloroquine and hydroxychloroquine in serum-starved BV-2 microglia. **2022**, 116084

41	Chloroquine modulates the sulforaphane anti-obesity mechanisms in a high-fat diet model: Role of JAK-2/ STAT-3/ SOCS-3 pathway. 2022 , 927, 175066	1
40	Therapeutic options in coronavirus treatment. 2022 , 101-135	
39	Evaluation of Nanoparticles with 5-Fluorouracil and Chloroquine on Acanthamoeba castellanii activity. 2022 , 111492	2
38	Outcomes of screening for hydroxychloroquine retinopathy at the Manchester Royal Eye Hospital: 2 years audit.	
37	The Anti-Histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits Infection by Major Variants of SARS-CoV-2 in Cell Cultures and Reconstituted Human Nasal Tissue. 13,	0
36	Repurposing the Antiplatelet Agent Ticlopidine to Counteract the Acute Phase of ER Stress Condition: An Opportunity for Fighting Coronavirus Infections and Cancer. 2022 , 27, 4327	
35	Impact of gamma-irradiation on the degradation and mineralization of hydroxychloroquine aqueous solutions.	1
34	Spectroscopic and Molecular Dynamics Aspect of Antimalarial Drug Hydroxychloroquine Binding with Human Telomeric G-Quadruplex.	1
33	Additively manufactured electrodes for the electrochemical detection of hydroxychloroquine. 2022 , 250, 123727	0
32	Contrasting Effect of Salts on the Binding of Antimalarial Drug Hydroxychloroquine with Different Sequences of Duplex DNA.	1
31	EBV-positive follicular lymphoma and concurrent EBV-negative diffuse large B-cell lymphoma illustrating branched evolution model and Hit and Run hypothesis.	0
30	Transcriptional landscapes and signaling pathways of chloroquine-treated Esophageal squamous cell carcinoma.	
29	A multi-spectroscopic and computational simulations study to delineate the interaction between antimalarial drug hydroxychloroquine and human serum albumin. 1-17	
28	Polygenic autoimmune disease risk alleles impacting B cell tolerance act in concert across shared molecular networks in mouse and in humans. 13,	0
27	Non-criteria antiphospholipid antibodies and pediatric rheumatic disease: a case series. 2022 , 20,	0
26	Effects of Hydroxychloroquine on markers of oxidative stress and antioxidant reserve in rheumatoid arthritis patients. 2022 , 12, 65-71	0
25	Drug repurposing in cancer neuroscience: From the viewpoint of the autophagy-mediated innervated niche. 13,	0
24	Acute and subacute oral toxicity of artemisinin-hydroxychloroquine sulfate tablets in beagle dogs. 1-9	0

23	Hydroxychloroquine attenuates autoimmune hepatitis by suppressing the interaction of GRK2 with PI3K in T lymphocytes. 13,	0
22	Effect of Graphite Exfoliation Way on the Efficiency of Exfoliated Graphene for the Determination of Hydroxychloroquine in Urine and Waste Water. 2022 , 169, 097505	0
21	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.	6
20	Candidate Drugs for the Potential Treatment of Coronavirus Diseases. 2021 , 85-114	0
19	Research trends and frontiers on antiphospholipid syndrome: A 10-year bibliometric analysis (2012-2021). 13,	0
18	A Green Approach: Eco-friendly Synthesis of Gd ₂ Ti ₂ O ₇ /N-GQD Nanocomposite and Photo-Degradation and Electrochemical Measurement of Hydroxychloroquine as a Perdurable Drug. 2022 , 104401	0
17	Low-cost zeolitic carriers for delivery of hydroxychloroquine immunomodulatory agent with antiviral activity. 2022 , 346, 112315	1
16	Tratamiento prehospitalario en COVID-19 atendidos en un hospital de referencia de la Ciudad de México. 2022 , 81, 80-85	0
15	Pathological changes in the osteoarticular system during COVID-19 drug therapy (review of literature). 2022 , 181, 85-91	0
14	The Role of Bone Morphogenetic Protein Receptor Type 2 (BMP2) and the Prospects of Utilizing Induced Pluripotent Stem Cells (iPSCs) in Pulmonary Arterial Hypertension Disease Modeling. 2022 , 11, 3823	0
13	Free radical induced degradation and computational studies of hydroxychloroquine in aqueous solution. 2023 , 110785	0
12	Effect of Hydroxychloroquine on Lupus Activity, Preeclampsia and Intrauterine Growth Restriction in Pregnant Women with Systemic Lupus Erythematosus and/or Antiphospholipid Syndrome: A Systematic Review and Meta-Analysis. 2023 , 12, 485	0
11	Progression of ECG in hydroxychloroquine overdose. 2023 , 77, 68-71	0
10	COVID-19: Inpatient Management. 2023 , 182-232	0
9	DFT Study Adsorption of Hydroxychloroquine for Treatment COVID-19 by SiC Nanotube and Al, Si Doping on Carbon Nanotube Surface: A Drug Delivery Simulation. 2022 , 96, 2953-2966	0
8	Antiphospholipid Syndrome. 2015 , 1-13	0
7	Antimalarials and macrolides: a review of off-label pharmacotherapies during the first wave of the SARS-CoV-2 pandemic. 59,	0
6	Single molecule force spectroscopy of DNA-ligand complexes in the entropic regime. 2023 , 135-182	0

- 5 Screening for toxic retinopathy due to antimalarial drugs in Tunisia. **2023**, 46, 356-362 ○
- 4 A Review of Pathology and Analysis of Approaches to Easing Kidney Disease Impact: Host-Pathogen Communication and Biomedical Visualization Perspective. **2023**, 41-57 ○
- 3 Bibliography. **2023**, 215-239 ○
- 2 Predicting Hydroxychloroquine Clearance in healthy and Diseased Populations Using a Physiologically Based Pharmacokinetic Approach. **2023**, 15, 1250 ○
- 1 Ocular microvascular alteration in Sjögren's syndrome treated with hydroxychloroquine: an OCTA clinical study. **2023**, 14, 204062232311644 ○